Staining:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Cytometry:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Apoptosis Assay:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Control:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Disruption:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Liquid Chromatography with Mass Spectroscopy:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Expressing:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
Western Blot:Article Title: Membrane repair triggered by cholesterol-dependent cytolysins is activated by mixed lineage kinases and MEK
Article Snippet: The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.The MAPK9/JNK1/2 inhibitor SP600125 (catalog no. S1460), pan-RAF inhibitor LY3009120 (catalog no. S7842), and PAK inhibitor FRAX597 (catalog no. S7271) were from Selleckchem.. PPMP was from Avanti Polar Lipids (Alabaster, AL, USA) (catalog no. 870792).. PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.PPMP was used at 40 μM in complete medium and incubated with cells for 48 hours before experiments.
Article Title: Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
Article Snippet: All primers were supplied by IDTDNA.All primers were supplied by IDTDNA.. PPMP and C 6 -ceramide nanoliposome drug studies C 6 -ceramide nanoliposomes were manufactured in our laboratory with the following lipids purchased from Avanti Polar Lipids: 1,2-distearoyl- sn -glycero-3-phosphocholine, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, N -hexanoyld -erythro-sphingosine (C 6 ), 1,2-distearoyl- sn -glycero-3phosphoethanolamine- N -[methoxy polyethylene glycol-2000] and N -octanoyl-sphingosine-1-[succinyl (methoxy polyethylene glycol-750)] [PEG(750)-C8], which were combined at a molar ratio of 3.75:1.75:3:0.75:0.75, respectively.. Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.Th e resultant C 6 -ceramide nanoliposomes contained 12% polyethylene glycol (PEG) to enable increased circulation time.
|